Paulwitz, Jan and Vonbrunn, Laura and Heller, Katharina and Dieterle, Anne and Apel, Hendrik and Schiffer, Mario and Wiesener, Michael S. and Dienemann, Thomas (2025) Preemptive Conversion to mTOR Inhibition to Prevent Primary Cytomegalovirus Infection in Kidney Transplantation with High-Risk Serostatus. TRANSPLANTATION PROCEEDINGS, 57 (5). pp. 784-792. ISSN 0041-1345, 1873-2623
Full text not available from this repository. (Request a copy)Abstract
Background. Kidney transplantation (KTx) is the treatment of choice for patients with end-stage renal disease. Cytomegalovirus (CMV) infection remains a serious complication of KTx. The most vulnerable patients are na & iuml;ve recipients (R-) transplanted from a CMV-seropositive donor (D+). Mammalian target of rapamycin inhibitors (mTOR-I) have been shown to have advantages over mycophenolate in terms of CMV infections. In this study, we addressed the effect of preemptive conversion to mTOR-I before ending prophylaxis with valganciclovir in high-risk patients with a D+/R-CMV serostatus. Methods. The study involved inclusion and analysis of all patients with D+/R-CMV serostatus before and after the protocol change with a conversion to mTOR-I at 6 months after KTx. The main study endpoints were primary CMV infection, maximal viral load, and hospitalization for CMV infection. Because prevention of primary CMV infections was the primary endpoint, we excluded breakthrough infections under prophylaxis. Results. The primary analysis included 44 patients in the control group and 39 patients in the mTOR group. The 2 groups did not have any significant differences in clinical characteristics, immunosuppressive treatment, transplant function, and rates of rejection. Between 6 and 12 months (when mTOR-I were established), the mTOR group showed a numerically lower incidence of CMV infections, as well as numerically fewer hospitalizations. No serious complications were observed with mTOR-I. Conclusion. Preemptive conversion from mycophenolate to mTOR-I may be helpful to prevent or attenuate primary infection in CMV high-risk kidney transplant recipients. Differences were not statistically significant. A larger study, ideally a prospective randomized trial, is needed to validate these findings.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | RECIPIENTS; VALGANCICLOVIR; EVEROLIMUS |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 12 Aug 2026 06:00 |
| Last Modified: | 12 Aug 2026 06:00 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67100 |
Actions (login required)
 |
View Item |
